<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antibiotic regimens for Shigella in children &lt;18 years of age&lt;sup&gt;[1-6]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antibiotic regimens for Shigella in children &lt;18 years of age<sup>[1-6]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Antibiotic regimens for Shigella in children &lt;18 years of age<sup>[1-6]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="20%"></colgroup><colgroup width="40%"></colgroup> <tbody> <tr> <td class="subtitle1">Antibiotic</td> <td class="subtitle1">Regimen</td> <td class="subtitle1">Maximum daily dose</td> <td class="subtitle1">Comments</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Parenteral agents for empiric or targeted therapy</td> </tr> <tr> <td class="indent1">Ceftriaxone (preferred)</td> <td>50 mg/kg IV or IM once daily for 5 days</td> <td>1.5 g/day</td> <td> <ul> <li>2 days of treatment may be sufficient for immunocompetent children without bacteremia who are afebrile after 2 days</li> </ul> </td> </tr> <tr> <td class="indent1">Ciprofloxacin</td> <td>20 mg/kg per day IV divided in 2 doses for 3 to 5 days</td> <td>800 mg/day</td> <td> <ul> <li>For children &lt;18 years: Use only if no other safe and effective alternative available</li> <li>Dose needs to be adjusted in setting of decreased/decreasing GFR</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Oral agents for empiric or targeted therapy</td> </tr> <tr> <td class="indent1">Azithromycin<br/> (preferred)</td> <td>12 mg/kg orally once daily on day 1; 6 mg/kg orally once daily for 2 to 4 days (total duration 3 to 5 days)</td> <td>500 mg/day on the first day;<br/> 250 mg/day on subsequent days</td> <td> <ul> <li>Preferred unless <em>Shigella</em> was acquired in South Asia (eg, India, Pakistan, Bangladesh)</li> </ul> </td> </tr> <tr> <td class="indent1">Cefixime</td> <td>8 mg/kg per day orally in 1 or 2 divided doses for 3 to 5 days</td> <td>400 mg/day</td> <td> <ul> <li>Preferred for <em>Shigella</em> acquired in South Asia (eg, India, Pakistan, Bangladesh)</li> </ul> </td> </tr> <tr> <td class="indent1">Ceftibuten</td> <td>9 mg/kg orally once daily for 3 to 5 days</td> <td>400 mg/day</td> <td> <ul> <li>Preferred for <em>Shigella</em> acquired in South Asia (eg, India, Pakistan, Bangladesh)</li> </ul> </td> </tr> <tr> <td class="indent1">Ciprofloxacin</td> <td>20 mg/kg per day orally in 2 divided doses for 3 to 5 days</td> <td>1.5 g/day</td> <td> <ul> <li>For children &lt;18 years: Use only if no other safe and effective alternative available</li> <li>Dose needs to be adjusted in setting of decreased/decreasing GFR</li> </ul> </td> </tr> <tr> <td class="indent1">Norfloxacin<br/> (not available in the United States)</td> <td>10 to 15 mg/kg per day orally in 2 divided doses for 3 to 5 days</td> <td>800 mg/day</td> <td> <ul> <li>For children &lt;18 years: Use only if no other safe and effective alternative available</li> <li>Dose needs to be adjusted in setting of decreased/decreasing GFR</li> </ul> </td> </tr> <tr> <td class="indent1">Pivmecillinam<br/> (not available in the United States)</td> <td>45 to 60 mg/kg per day orally in 3 or 4 divided doses for 3 to 5 days</td> <td>900 mg/day</td> <td>Â </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Oral agents primarily for targeted therapy</td> </tr> <tr> <td class="indent1">Ampicillin</td> <td>100 mg/kg per day orally in 4 divided doses for 3 to 5 days</td> <td>2 g/day</td> <td> <ul> <li>Use only if: </li> </ul> <ul class="decimal_heading"> <li>The isolated strain is susceptible, or</li> <li>Local microbiologic data suggest susceptibility</li> </ul> </td> </tr> <tr> <td class="indent1">Nalidixic acid<br/> (not available in the United States)</td> <td>55 mg/kg per day orally divided in 4 doses for 3 to 5 days</td> <td>4 g/day</td> <td> <ul> <li>For children &lt;18 years: Use only if no other safe and effective alternative available</li> </ul> <ul> <li>Use only if: </li> </ul> <ul class="decimal_heading"> <li>The isolated strain is susceptible, or</li> <li>Local microbiologic data suggest susceptibility</li> <li>Dose needs to be adjusted in setting of decreased/decreasing GFR</li> </ul> </td> </tr> <tr> <td class="indent1">Trimethoprim-sulfamethoxazole<br/> (Co-trimoxazole, TMP-SMX)</td> <td>10 mg/kg (based upon TMP component) orally in 2 divided doses for 3 to 5 days</td> <td>320 mg TMP/day</td> <td> <ul> <li>Use only if: </li> </ul> <ul class="decimal_heading"> <li>The isolated strain is susceptible, or</li> <li>Local microbiologic data suggest susceptibility</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">This table is meant for use with UpToDate content on treatment of shigella infections in children. Refer to UpToDate content for additional details, including choice of therapy and follow-up.</div><div class="graphic_footnotes">IV: intravenous;
	IM: intramuscular;
	GFR: glomerular filtration rate.</div><div class="graphic_reference">References:
	<ol>
<li>American Academy of Pediatrics. Shigella infections. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32<sup>nd</sup> ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.668.</li>
<li>Eidlitz-Marcus T, Cohen YH, Nussinovitch M, et al. Comparative efficacy of two- and five-day courses of ceftriaxone for treatment of severe shigellosis in children. J Pediatr 1993; 123:822.</li>
<li>Jackson MA, Schutze GE, Committee on Infectious Diseases. The use of systemic and topical fluoroquinolones. Pediatrics 2016; 138.</li>
<li>Martin JM, Pitetti R, Maffei F, et al. Treatment of shigellosis with cefixime: Two days vs. five days. Pediatr Infect Dis J 2000; 19:522.</li>
<li>Salam MA, Dhar U, Khan WA, Bennish ML. Randomised comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis. Lancet 1998; 352:522.</li>
<li>Basualdo W, Arbo A. Randomized comparison of azithromycin versus cefixime for treatment of shigellosis in children. Pediatr Infect Dis J 2003; 22:374.</li>
</ol></div><div id="graphicVersion">Graphic 88651 Version 12.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
